Rakuten Medical CEO Minami Maeda discusses the company’s ongoing Phase 3 trial, its target of a 2028 FDA submission and the additional capital needed to reach U.S. commercialization. He also outlines plans for global expansion, including potential public or private funding and strategic partnerships.Read More
